SCHEMBL4564743

SCHEMBL4564743

Nc1ccc(NC(=O)C2CCCNC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 1/20 0.64
▸ ALOX15 P16050 1/20 0.52
▸ PTPN1 P18031 1/20 0.51
▸ TNKS O95271 1/20 0.49
▸ TNKS2 Q9H2K2 1/20 0.49
▸ MAPT P10636 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ ATM Q13315 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ ROCK2 O75116 1/20 0.48
▸ HPGD P15428 1/20 0.47
▸ F10 P00742 1/20 0.47
▸ KHK P50053 1/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ EPHX1 P07099 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ SLC6A1 P30531 2/20 0.46
▸ SLC6A11 P48066 1/20 0.46
▸ TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154722 0.87 ULK1 (0.57) ULK1ALOX15PTPN1TNKSTNKS2
SCHEMBL2448229 0.87 ULK1 (0.56) ULK1ALOX15PTPN1TNKSTNKS2
SCHEMBL2449552 0.87 ULK1 (0.56) ULK1ALOX15PTPN1TNKSTNKS2
SCHEMBL2451482 0.87 ULK1 (0.56) ULK1RAB9A
SCHEMBL1318166 0.86 HPGD (0.66) ULK1ALOX15PTPN1TNKSTNKS2
SCHEMBL1318173 0.86 HPGD (0.66) ULK1ALOX15PTPN1TNKSTNKS2
SCHEMBL2446479 0.86 HPGD (0.66) ULK1ALOX15PTPN1TNKSTNKS2
Hydrochloric Acid SCHEMBL193349 0.85 ULK1 (0.55) ULK1ALOX15PTPN1TNKSTNKS2
Hydrochloric Acid SCHEMBL4033476 0.85 HPGD (0.64) ULK1ALOX15PTPN1TNKSTNKS2
SCHEMBL4448787 0.84 PTPN1 (0.71) PTPN1MAPTKMT2AHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099453-A2 COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES Bayer Schering Pharma Aktiengesellschaft (DE) 2009-09-16 — — EP disclosed
EP-1933841-A1 COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS Bayer HealthCare AG (DE) 2008-06-25 — — EP disclosed
WO-2008052671-A2 COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-05-08 — — WO disclosed
WO-2007039134-A1 COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS BAYER HEALTHCARE AG (DE) 2007-04-12 — — WO disclosed
EP-1411932-A1 SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY Bayer HealthCare AG (DE) 2004-04-28 — — EP disclosed
WO-2003000256-A1 SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY BAYER HEALTHCARE AG (DE) 2003-01-03 — — WO disclosed
WO-2001047919-A9 SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION BAYER AG (DE) 2002-12-19 — — WO disclosed
EP-1261606-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION Bayer Aktiengesellschaft (DE) 2002-12-04 — — EP disclosed
WO-2001047919-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION BAYER AKTIENGESELLSCHAFT (DE) 2001-07-05 — — WO disclosed
Send feedback